Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Department of Gynecology and Obstetrics, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Clin Breast Cancer. 2024 Jan;24(1):e9-e19.e9. doi: 10.1016/j.clbc.2023.09.013. Epub 2023 Sep 26.
Breast cancer is one of the most common cancers in the world. It is a multifaceted malignancy with different histopathological and biological features. Molecular biomarkers play an essential role in accurate diagnosis, classification, prognosis, prediction of treatment response, and cancer surveillance. This study investigated the clinico-pathological and prognostic significance of HER3 and ROR1 in breast cancer samples.
Tissue microarrays (TMA) were constructed using tissue blocks of 444 Iranian breast cancer patients diagnosed with breast cancer. Overall survival (OS) and disease-free survival (DFS) were assessed after 5 years follow-up. TMA slides were stained with monoclonal antibodies against ROR1, HER3, ER, PR, Ki67, P53, HER2 and CK5/6 using IHC and correlation between the investigated tumor markers and the clinico-pathological parameters of patients were analyzed.
Our results showed a significant correlation between ROR1 and ER, PR, HER3, and CK5/6 expression. Additionally, there was a significant correlation between HER3 and ER, PR, HER2, and Ki67 expression. Ki67 was also correlated with HER2 and P53 expression. HER3 expression was significantly correlated with tumor stage, lymph node metastasis, perineural invasion, and multifocal tumors. Furthermore, ROR1 expression was significantly associated with tumor metastasis, lympho-vascular invasion, and perineural invasion. While HER2-HER3 coexpression was significantly associated with poor OS, HER3-ROR1 coexpression was associated with lymph node invasion, lymph node metastasis, and distant metastasis.
ROR1 and HER3 displayed significant association with different clinic-pathological features and in addition to the other tumor biomarkers could be considered as diagnostic and prognostic biomarkers in breast cancer patients.
乳腺癌是世界上最常见的癌症之一。它是一种具有不同组织病理学和生物学特征的多方面恶性肿瘤。分子生物标志物在准确诊断、分类、预后、预测治疗反应和癌症监测方面发挥着重要作用。本研究探讨了 HER3 和 ROR1 在乳腺癌样本中的临床病理和预后意义。
使用 444 名伊朗乳腺癌患者的组织块构建组织微阵列(TMA)。对 5 年随访后的总生存(OS)和无病生存(DFS)进行评估。使用 IHC 对 TMA 切片进行针对 ROR1、HER3、ER、PR、Ki67、P53、HER2 和 CK5/6 的单克隆抗体染色,并分析所研究的肿瘤标志物与患者临床病理参数之间的相关性。
我们的结果表明,ROR1 与 ER、PR、HER3 和 CK5/6 的表达之间存在显著相关性。此外,HER3 与 ER、PR、HER2 和 Ki67 的表达之间也存在显著相关性。Ki67 还与 HER2 和 P53 的表达相关。HER3 表达与肿瘤分期、淋巴结转移、神经周围浸润和多灶性肿瘤显著相关。此外,ROR1 表达与肿瘤转移、淋巴管侵犯和神经周围浸润显著相关。而 HER2-HER3 共表达与较差的 OS 显著相关,HER3-ROR1 共表达与淋巴结浸润、淋巴结转移和远处转移相关。
ROR1 和 HER3 与不同的临床病理特征显著相关,除了其他肿瘤标志物外,还可以作为乳腺癌患者的诊断和预后生物标志物。